Discontinued — last reported Q1 '26
Pharmaceutical — Income (Loss) from Equity Method Investments
Merck & Co. Pharmaceutical — Income (Loss) from Equity Method Investments increased by 51.2% to $62.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.9%, from $58.00M to $62.00M. Over 4 years (FY 2021 to FY 2025), Pharmaceutical — Income (Loss) from Equity Method Investments shows an upward trend with a 103.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
Positive income indicates successful strategic partnerships, while losses may signal underperformance of joint ventures.
Detailed definition
The segment's share of profits or losses from companies in which it holds a significant influence but not a controlling...
Peer comparison
Common in pharma where companies frequently use joint ventures to share the risk of drug development.
mrk_segment_pharmaceutical_segment_income_loss_from_equity_method_investmentsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$2.75M | -$2.75M | -$2.75M | $9.75M | $9.75M | $9.75M | $9.75M | $27.75M | $27.75M | $27.75M | $27.75M | $48.00M | $29.00M | $43.00M | $24.00M | $58.00M | $29.00M | $62.00M | $41.00M | $62.00M |
| QoQ Change | — | +0.0% | +0.0% | +454.5% | +0.0% | +0.0% | +0.0% | +184.6% | +0.0% | +0.0% | +0.0% | +73.0% | -39.6% | +48.3% | -44.2% | +141.7% | -50.0% | +113.8% | -33.9% | +51.2% |
| YoY Change | — | — | — | — | +454.5% | +454.5% | +454.5% | +184.6% | +184.6% | +184.6% | +184.6% | +73.0% | +4.5% | +55.0% | -13.5% | +20.8% | +0.0% | +44.2% | +70.8% | +6.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s pharmaceutical — income (loss) from equity method investments?
- Merck & Co. (MRK) reported pharmaceutical — income (loss) from equity method investments of $62.00M in Q1 2026.
- How has Merck & Co.'s pharmaceutical — income (loss) from equity method investments changed year-over-year?
- Merck & Co.'s pharmaceutical — income (loss) from equity method investments increased by 6.9% year-over-year, from $58.00M to $62.00M.
- What is the long-term trend for Merck & Co.'s pharmaceutical — income (loss) from equity method investments?
- Over 4 years (2021 to 2025), Merck & Co.'s pharmaceutical — income (loss) from equity method investments has grown at a 103.9% compound annual growth rate (CAGR), from -$11.00M to $190.00M.
- What does pharmaceutical — income (loss) from equity method investments mean?
- The segment's portion of earnings from companies it partially owns.